|
US4711955A
(en)
|
1981-04-17 |
1987-12-08 |
Yale University |
Modified nucleotides and methods of preparing and using same
|
|
US4769330A
(en)
|
1981-12-24 |
1988-09-06 |
Health Research, Incorporated |
Modified vaccinia virus and methods for making and using the same
|
|
US4603112A
(en)
|
1981-12-24 |
1986-07-29 |
Health Research, Incorporated |
Modified vaccinia virus
|
|
CA1223831A
(en)
|
1982-06-23 |
1987-07-07 |
Dean Engelhardt |
Modified nucleotides, methods of preparing and utilizing and compositions containing the same
|
|
FR2643817B1
(fr)
|
1989-03-06 |
1993-12-17 |
Transgene Sa |
Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
|
|
DE3642912A1
(de)
|
1986-12-16 |
1988-06-30 |
Leybold Ag |
Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
|
|
FR2632863B2
(fr)
|
1987-10-29 |
1990-08-31 |
Transgene Sa |
Virus du fowlpox recombinant et vaccins derives de ces virus
|
|
US5100587A
(en)
|
1989-11-13 |
1992-03-31 |
The United States Of America As Represented By The Department Of Energy |
Solid-state radioluminescent zeolite-containing composition and light sources
|
|
US5756102A
(en)
|
1990-11-20 |
1998-05-26 |
Virogenetics Corporation |
Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
|
|
DE69233158T2
(de)
|
1991-03-07 |
2004-05-13 |
Connaught Technology Corp., Greenville |
Gentechnologisch hergestellter stamm für impfstoffe
|
|
GB9105383D0
(en)
*
|
1991-03-14 |
1991-05-01 |
Immunology Ltd |
An immunotherapeutic for cervical cancer
|
|
US5179993A
(en)
|
1991-03-26 |
1993-01-19 |
Hughes Aircraft Company |
Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
|
|
DE4123760C2
(de)
|
1991-07-18 |
2000-01-20 |
Dade Behring Marburg Gmbh |
Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
|
|
US6013638A
(en)
|
1991-10-02 |
2000-01-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
|
|
GB9223084D0
(en)
|
1992-11-04 |
1992-12-16 |
Imp Cancer Res Tech |
Compounds to target cells
|
|
US5674703A
(en)
*
|
1992-12-02 |
1997-10-07 |
Woo; Savio L. C. |
Episomal vector systems and related methods
|
|
FR2705686B1
(fr)
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
|
US6133028A
(en)
|
1993-05-28 |
2000-10-17 |
Transgene S.A. |
Defective adenoviruses and corresponding complementation lines
|
|
US5698443A
(en)
|
1995-06-27 |
1997-12-16 |
Calydon, Inc. |
Tissue specific viral vectors
|
|
ATE328068T1
(de)
*
|
1994-05-16 |
2006-06-15 |
Merck & Co Inc |
Papillomavirus vakzine
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
US6638762B1
(en)
|
1994-11-28 |
2003-10-28 |
Genetic Therapy, Inc. |
Tissue-vectors specific replication and gene expression
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
FR2727689A1
(fr)
|
1994-12-01 |
1996-06-07 |
Transgene Sa |
Nouveau procede de preparation d'un vecteur viral
|
|
US5837520A
(en)
|
1995-03-07 |
1998-11-17 |
Canji, Inc. |
Method of purification of viral vectors
|
|
FR2749323B1
(fr)
|
1996-06-04 |
1998-07-10 |
Pasteur Merieux Serums Vacc |
Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
|
|
IL127692A0
(en)
|
1996-07-01 |
1999-10-28 |
Rhone Poulenc Rorer Sa |
Method for producing recombinant adenovirus
|
|
WO1998022588A2
(en)
|
1996-11-20 |
1998-05-28 |
Introgen Therapeutics, Inc. |
An improved method for the production and purification of adenoviral vectors
|
|
AU5370598A
(en)
|
1996-12-13 |
1998-07-03 |
Schering Corporation |
Methods for purifying viruses
|
|
WO1998056415A1
(en)
|
1997-06-11 |
1998-12-17 |
Aquila Biopharmaceuticals, Inc. |
Purified saponins as oral adjuvants
|
|
FR2766091A1
(fr)
*
|
1997-07-18 |
1999-01-22 |
Transgene Sa |
Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
|
|
WO1999014377A2
(en)
|
1997-09-16 |
1999-03-25 |
Innogenetics N.V. |
Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization
|
|
FR2774699B1
(fr)
*
|
1997-11-17 |
2003-10-03 |
Rhone Poulenc Rorer Sa |
Methode de reduction des evenements de recombinaison homologue
|
|
FR2777570A1
(fr)
|
1998-04-17 |
1999-10-22 |
Transgene Sa |
Mutant ayant une activite phosphoribosyl transferase
|
|
JP3864610B2
(ja)
|
1998-05-21 |
2007-01-10 |
旭硝子株式会社 |
水分散型撥水撥油剤組成物およびその製造方法
|
|
US6900049B2
(en)
|
1998-09-10 |
2005-05-31 |
Cell Genesys, Inc. |
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
|
|
US20020037274A1
(en)
|
1998-10-26 |
2002-03-28 |
Angelica Williams |
Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
|
|
US6582693B2
(en)
*
|
1998-11-30 |
2003-06-24 |
Lemery, S.A. De C.V. |
Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses
|
|
FR2787465A1
(fr)
|
1998-12-21 |
2000-06-23 |
Transgene Sa |
Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
|
|
NZ512504A
(en)
|
1998-12-31 |
2004-01-30 |
Aventis Pharma Sa |
Method for separating viral particles
|
|
EP1147181B1
(en)
|
1999-02-04 |
2004-05-12 |
Geron Corporation |
Replicative virus driven by the promoter for telomerase reverse transcriptase for use in treating cancer
|
|
JP4802366B2
(ja)
|
1999-02-22 |
2011-10-26 |
トランスジェン・ソシエテ・アノニム |
精製ウイルス調製物の取得方法
|
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
|
EP1212358B1
(en)
|
1999-08-25 |
2004-12-15 |
Merck & Co., Inc. |
Synthetic papillomavirus genes optimized for expression in human cells
|
|
CN1382218A
(zh)
|
1999-11-15 |
2002-11-27 |
昂尼克斯药物公司 |
溶瘤腺病毒
|
|
CA2341356C
(en)
|
2000-04-14 |
2011-10-11 |
Transgene S.A. |
Poxvirus with targeted infection specificity
|
|
US20020029498A1
(en)
*
|
2000-07-03 |
2002-03-14 |
Howard Harrison |
Rapid cool iron and related iron improvements
|
|
HK1056195B
(en)
|
2000-07-21 |
2007-06-22 |
Glaxo Group Limited |
Codon-optimized papilloma virus sequences
|
|
AU2002344190B2
(en)
|
2001-05-30 |
2007-10-18 |
Transgene S.A. |
Adenovirus protein IX, Its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
|
|
CA2457890A1
(en)
|
2001-08-23 |
2003-03-06 |
Merck & Co., Inc. |
Vaccine using papillomavirus e proteins delivered by viral vector
|
|
ATE315660T1
(de)
*
|
2002-05-16 |
2006-02-15 |
Bavarian Nordic As |
Intergene regionen als insertionsstellen im genom von modifiziertem vaccinia virus ankara (mva)
|
|
GB0222953D0
(en)
*
|
2002-10-03 |
2002-11-13 |
Glaxo Group Ltd |
Novel Compounds
|
|
AU2003290460A1
(en)
*
|
2003-12-24 |
2005-07-14 |
Leiden University Medical Center |
Synthetic protein as tumor-specific vaccine
|
|
AU2005222776A1
(en)
|
2003-12-31 |
2005-09-29 |
Genimmune N.V. |
Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
|